The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×2•Originally published 4 April 2026•Updated 5 April 2026•

1 min read

Lawsuit Filed Against uniQure Following Public Rebukes from US FDA

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Law firm Hagens Berman is updating its investigation into uniQure N.V. (QURE) following public rebukes from the FDA.

about 2 months ago

Version History

3 additional sources confirmed this story

Version 2about 2 months ago

What changed: The legal situation escalated from an investigation to a formal lawsuit, and a specific shareholder deadline of April 13, 2026, was established.

Version 12 months ago

A class action lawsuit has been officially filed against uniQure N.V. (QURE), marking a significant escalation from the initial investigation stage. The legal action follows extraordinary public rebukes from the U.S. Food and Drug Administration (FDA) regarding allegations of "distorted" and inaccurate data submissions. The lawsuit claims that the company’s leadership misled investors and compromised the integrity of its reported clinical findings. A specific court-related deadline of April 13, 2026, has now been established for shareholders to join the class action. This litigation aims to recover financial losses suffered by investors due to the alleged misrepresentations and their impact on the company's market value. Analysts expect QURE shares to remain under pressure as the legal process unfolds and regulatory scrutiny intensifies.